X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (64) 64
oncology (61) 61
humans (60) 60
colorectal cancer (25) 25
cancer (24) 24
mutation (24) 24
female (21) 21
colorectal neoplasms - genetics (18) 18
antineoplastic agents - therapeutic use (16) 16
colorectal neoplasms - drug therapy (16) 16
aged (15) 15
middle aged (15) 15
neoplasms - drug therapy (15) 15
tumors (15) 15
adult (13) 13
chemotherapy (13) 13
care and treatment (12) 12
male (12) 12
antineoplastic agents - pharmacology (11) 11
hematology, oncology and palliative medicine (11) 11
microsatellite instability (11) 11
mutations (11) 11
acquired-resistance (10) 10
biomarkers (10) 10
breast-cancer (10) 10
colorectal-cancer (10) 10
neoplasms - genetics (10) 10
prognosis (10) 10
research (10) 10
targeted therapy (10) 10
animals (9) 9
colon-cancer (9) 9
genomics (9) 9
molecular targeted therapy (9) 9
precision medicine (9) 9
treatment outcome (9) 9
cell line, tumor (8) 8
colorectal neoplasms - metabolism (8) 8
colorectal neoplasms - pathology (8) 8
medicine (8) 8
open-label (8) 8
protein kinase inhibitors - pharmacology (8) 8
proto-oncogene proteins b-raf - genetics (8) 8
receptor, epidermal growth factor - antagonists & inhibitors (8) 8
therapy (8) 8
1st-line treatment (7) 7
aged, 80 and over (7) 7
analysis (7) 7
biomarkers, tumor - genetics (7) 7
clinical trials (7) 7
colorectal carcinoma (7) 7
dose-response relationship, drug (7) 7
gene expression (7) 7
growth-factor receptor (7) 7
health aspects (7) 7
kras mutations (7) 7
neoplasm staging (7) 7
signal transduction - drug effects (7) 7
article (6) 6
braf (6) 6
braf mutation (6) 6
cancer therapies (6) 6
cetuximab (6) 6
neoplasms - metabolism (6) 6
panitumumab (6) 6
patient selection (6) 6
patients (6) 6
protein kinase inhibitors - therapeutic use (6) 6
biomarker (5) 5
biomarkers, tumor - metabolism (5) 5
carcinoma (5) 5
cell biology (5) 5
clinical trials as topic (5) 5
disease-free survival (5) 5
double-blind (5) 5
genomes (5) 5
kras (5) 5
lung cancer (5) 5
medical research (5) 5
metastasis (5) 5
mice (5) 5
neoplasm metastasis (5) 5
original (5) 5
phosphatidylinositol 3-kinases - antagonists & inhibitors (5) 5
pi3k (5) 5
randomized-trial (5) 5
ras mutations (5) 5
review (5) 5
survival (5) 5
tyrosine kinase inhibitor (5) 5
antitumor-activity (4) 4
biomarkers, tumor (4) 4
breast cancer (4) 4
cell lung-cancer (4) 4
colorectal neoplasms - mortality (4) 4
consensus molecular subtypes (4) 4
consolidation (4) 4
drug development (4) 4
drug therapy (4) 4
epidermal growth factor receptors (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 12/2019, Volume 30, Issue Supplement_11
Abstract Background A combination therapy based on chemotherapy (CT) and Anti-PD1 is the new standard FDA-approved first-line treatment for (R/M) HNSCC PD-L1... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2019, Volume 30, Issue Supplement_11
Abstract Background Baseline derived neutrophil–lymphocyte ratio (dNLR) and LDH are prognostic biomarkers for IT in lung cancer. Immune-related adverse events... 
Journal Article
Nature Genetics, ISSN 1061-4036, 01/2017, Volume 49, Issue 2, pp. 170 - 174
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 03/2013, Volume 10, Issue 3, pp. 143 - 153
The phosphatidylinositol 3-kinase (PI3K) pathway has an important role in cell metabolism, growth, migration, survival and angiogenesis. Drug development aimed... 
DOSE-ESCALATION | IN-VITRO | EFFICACY | ONCOLOGY | COLORECTAL-CANCER | SURROGATE TISSUES | KINASE | PATHWAY INHIBITION | PHASE-I | 3-KINASE INHIBITORS | CANCER CELL-LINES | Humans | Neoplasm Proteins - physiology | Substrate Specificity | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | Protein Processing, Post-Translational - drug effects | Antineoplastic Agents - adverse effects | TOR Serine-Threonine Kinases - physiology | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Isoenzymes - physiology | Sirolimus - therapeutic use | Neoplasms - enzymology | Mice, Transgenic | Clinical Trials as Topic | Proto-Oncogene Proteins c-akt - physiology | Signal Transduction - genetics | Sirolimus - pharmacology | Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Biomarkers | Phosphatidylinositol 3-Kinases - physiology | Mice | Protein Kinase Inhibitors - pharmacology | Isoenzymes - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - antagonists & inhibitors
Journal Article
Nature medicine, ISSN 1078-8956, 2015, Volume 21, Issue 11, pp. 1350 - 1356
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2018, Volume 24, Issue 5, pp. 989 - 990
It has long since been recognized that colorectal cancer is molecularly heterogeneous and its clinical behavior differs if the primary tumor was located in the... 
COLONOSCOPY | ONCOLOGY | Colon | Colorectal carcinoma | Colorectal cancer | Cancer
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 148, Issue 1, pp. 88 - 99
Background & Aims Categorization of colon cancers into distinct subtypes using a combination of pathway-based biomarkers could provide insight into... 
Gastroenterology and Hepatology | Colorectal Cancer | Genetics | Oncogene | Prognostic Factor | ADJUVANT CHEMOTHERAPY | BRAF MUTATION STATUS | TRIAL CALGB 89803 | RANDOMIZED-TRIAL | V600E MUTATION | MICROSATELLITE-INSTABILITY | KRAS-MUTATION | COLORECTAL-CANCER | RAS MUTATIONS | GASTROENTEROLOGY & HEPATOLOGY | MISMATCH-REPAIR STATUS | MutL Protein Homolog 1 | Predictive Value of Tests | Colonic Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma - pathology | Colonic Neoplasms - classification | Prospective Studies | Adenocarcinoma - classification | Humans | Middle Aged | DNA-Binding Proteins - analysis | Male | Young Adult | Time Factors | DNA Mismatch Repair | Aged, 80 and over | Colonic Neoplasms - therapy | Genetic Predisposition to Disease | Risk Factors | Adaptor Proteins, Signal Transducing - analysis | Phenotype | Adenocarcinoma - therapy | Biomarkers, Tumor - genetics | Mutation | ras Proteins - genetics | Nuclear Proteins - analysis | DNA Mutational Analysis - methods | DNA Methylation | Polymerase Chain Reaction | Adult | Female | Adenocarcinoma - genetics | Nuclear Proteins - genetics | Promoter Regions, Genetic | Colonic Neoplasms - mortality | Reproducibility of Results | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Adaptor Proteins, Signal Transducing - genetics | Aged | MutS Homolog 2 Protein - analysis | Neoplasm Staging | Adenocarcinoma - mortality | Cancer patients | Patient outcomes | Colon cancer | colorectal cancer | genetics | prognostic factor | oncogene
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 11, pp. 2889 - 2890
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2014, Volume 25, Issue 11, pp. 2244 - 2251
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 05/2017, Volume 28, Issue 5, pp. 1023 - 1031
Journal Article
Annals of Oncology, ISSN 0923-7534, 2015, Volume 26, Issue 8, pp. 1523 - 1525
Journal Article
NATURE, ISSN 0028-0836, 08/2017, Volume 548, Issue 7665, pp. 40 - 41
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 11/2019, Volume 30, Issue 11, pp. 1682 - 1685
Journal Article